A tailored phase I-specific patient-reported outcome (PRO) survey to capture the patient experience of symptomatic adverse events.

Autor: Janse van Rensburg HJ; Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, ON, Canada., Liu Z; Department of Biostatistics, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, ON, Canada., Watson GA; Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, ON, Canada., Veitch ZW; Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, ON, Canada., Shepshelovich D; Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, ON, Canada.; Medicine D, Tel-Aviv Medical Center and the Sackler School of Medicine, Tel Aviv, Israel., Spreafico A; Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, ON, Canada., Abdul Razak AR; Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, ON, Canada., Bedard PL; Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, ON, Canada., Siu LL; Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, ON, Canada., Minasian L; National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Hansen AR; Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, ON, Canada. aaron.r.hansen@health.qld.gov.au.; Faculty of Medicine, University of Queensland, Brisbane, QLD, Australia. aaron.r.hansen@health.qld.gov.au.

Publikováno v: British journal of cancer [Br J Cancer] 2023 Sep; Vol. 129 (4), pp. 612-619. Date of Electronic Publication: 2023 Jul 07.

Longitudinal efficacy and toxicity of SARS-CoV-2 vaccination in cancer patients treated with immunotherapy.

Autor: Spiliopoulou P; Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada., Janse van Rensburg HJ; Department of Internal Medicine, University of Toronto, Toronto, ON, Canada., Avery L; Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada., Kulasingam V; Laboratory Medicine Program, University Health Network, Toronto, ON, Canada., Razak A; Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada., Bedard P; Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada., Hansen A; Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada., Chruscinski A; Mutli-Organ Transplant Program, University Health Network, Toronto, ON, Canada., Wang B; Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada., Kulikova M; Laboratory Medicine Program, University Health Network, Toronto, ON, Canada., Chen R; Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada., Speers V; Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada., Nguyen A; Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada., Lee J; Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada., Coburn B; Laboratory Medicine Program, University Health Network, Toronto, ON, Canada., Spreafico A; Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada., Siu LL; Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada. lillian.siu@uhn.ca.

Publikováno v: Cell death & disease [Cell Death Dis] 2023 Jan 20; Vol. 14 (1), pp. 49. Date of Electronic Publication: 2023 Jan 20.

Luciferase-Based Biosensors in the Era of the COVID-19 Pandemic.

Autor: Azad T; Centre for Innovative Cancer Research, Ottawa Hospital Research Institute, Ottawa K1H 8L6, Canada.; Department of Biochemistry, Microbiology and Immunology, University of Ottawa, Ottawa K1H 8M5, Canada., Janse van Rensburg HJ; Department of Medicine, University of Toronto, Toronto, Ontario M5S 3H2, Canada., Morgan J; Centre for Innovative Cancer Research, Ottawa Hospital Research Institute, Ottawa K1H 8L6, Canada.; Department of Biochemistry, Microbiology and Immunology, University of Ottawa, Ottawa K1H 8M5, Canada., Rezaei R; Centre for Innovative Cancer Research, Ottawa Hospital Research Institute, Ottawa K1H 8L6, Canada.; Department of Biochemistry, Microbiology and Immunology, University of Ottawa, Ottawa K1H 8M5, Canada., Crupi MJF; Centre for Innovative Cancer Research, Ottawa Hospital Research Institute, Ottawa K1H 8L6, Canada.; Department of Biochemistry, Microbiology and Immunology, University of Ottawa, Ottawa K1H 8M5, Canada., Chen R; Centre for Innovative Cancer Research, Ottawa Hospital Research Institute, Ottawa K1H 8L6, Canada.; Department of Biochemistry, Microbiology and Immunology, University of Ottawa, Ottawa K1H 8M5, Canada., Ghahremani M; Canada Department of Biology, University of Ottawa, Ottawa K1N 6N5, Canada., Jamalkhah M; Centre for Innovative Cancer Research, Ottawa Hospital Research Institute, Ottawa K1H 8L6, Canada.; Department of Biochemistry, Microbiology and Immunology, University of Ottawa, Ottawa K1H 8M5, Canada., Forbes N; Centre for Communicable Diseases and Infection Control, Public Health Agency of Canada, Ottawa K2E 1B6, Canada., Ilkow C; Centre for Innovative Cancer Research, Ottawa Hospital Research Institute, Ottawa K1H 8L6, Canada.; Department of Biochemistry, Microbiology and Immunology, University of Ottawa, Ottawa K1H 8M5, Canada., Bell JC; Centre for Innovative Cancer Research, Ottawa Hospital Research Institute, Ottawa K1H 8L6, Canada.; Department of Biochemistry, Microbiology and Immunology, University of Ottawa, Ottawa K1H 8M5, Canada.

Publikováno v: ACS nanoscience Au [ACS Nanosci Au] 2021 Aug 09; Vol. 1 (1), pp. 15-37. Date of Electronic Publication: 2021 Aug 09 (Print Publication: 2021).

Rox8 promotes microRNA-dependent yki messenger RNA decay.

Autor: Guo X; Institute of Intervention Vessel, Shanghai 10th People's Hospital, Shanghai Key Laboratory of Signaling and Diseases Research, School of Life Science and Technology, Tongji University, Shanghai 200092, China., Sun Y; Institute of Intervention Vessel, Shanghai 10th People's Hospital, Shanghai Key Laboratory of Signaling and Diseases Research, School of Life Science and Technology, Tongji University, Shanghai 200092, China.; Zhuhai Interventional Medical Center, Zhuhai Precision Medical Center, Zhuhai People's Hospital, Zhuhai Hospital Affiliated with Jinan University, Zhuhai, Guangdong 51900, China., Azad T; Department of Pathology and Molecular Medicine, Queen's University, Kingston, K7L 3N6, ON, Canada., Janse van Rensburg HJ; Department of Pathology and Molecular Medicine, Queen's University, Kingston, K7L 3N6, ON, Canada., Luo J; Institute of Intervention Vessel, Shanghai 10th People's Hospital, Shanghai Key Laboratory of Signaling and Diseases Research, School of Life Science and Technology, Tongji University, Shanghai 200092, China., Yang S; Key Laboratory of Growth Regulation and Translational Research of Zhejiang Province, School of Life Sciences, Westlake University, Hangzhou, Zhejiang 310024, China.; Institute of Biology, Westlake Institute for Advanced Study, Hangzhou, Zhejiang 310024, China., Liu P; Key Laboratory of Growth Regulation and Translational Research of Zhejiang Province, School of Life Sciences, Westlake University, Hangzhou, Zhejiang 310024, China.; Institute of Biology, Westlake Institute for Advanced Study, Hangzhou, Zhejiang 310024, China., Lv Z; Institute of Intervention Vessel, Shanghai 10th People's Hospital, Shanghai Key Laboratory of Signaling and Diseases Research, School of Life Science and Technology, Tongji University, Shanghai 200092, China., Zhan M; Zhuhai Interventional Medical Center, Zhuhai Precision Medical Center, Zhuhai People's Hospital, Zhuhai Hospital Affiliated with Jinan University, Zhuhai, Guangdong 51900, China., Lu L; Zhuhai Interventional Medical Center, Zhuhai Precision Medical Center, Zhuhai People's Hospital, Zhuhai Hospital Affiliated with Jinan University, Zhuhai, Guangdong 51900, China., Zhou Y; Institute of Intervention Vessel, Shanghai 10th People's Hospital, Shanghai Key Laboratory of Signaling and Diseases Research, School of Life Science and Technology, Tongji University, Shanghai 200092, China., Ma X; Key Laboratory of Growth Regulation and Translational Research of Zhejiang Province, School of Life Sciences, Westlake University, Hangzhou, Zhejiang 310024, China; lei.xue@tongji.edu.cn maxianjue@westlake.edu.cn zxpkxy@126.com yangx@queensu.ca.; Institute of Biology, Westlake Institute for Advanced Study, Hangzhou, Zhejiang 310024, China., Zhang X; Institute of Intervention Vessel, Shanghai 10th People's Hospital, Shanghai Key Laboratory of Signaling and Diseases Research, School of Life Science and Technology, Tongji University, Shanghai 200092, China; lei.xue@tongji.edu.cn maxianjue@westlake.edu.cn zxpkxy@126.com yangx@queensu.ca., Yang X; Department of Pathology and Molecular Medicine, Queen's University, Kingston, K7L 3N6, ON, Canada; lei.xue@tongji.edu.cn maxianjue@westlake.edu.cn zxpkxy@126.com yangx@queensu.ca., Xue L; Institute of Intervention Vessel, Shanghai 10th People's Hospital, Shanghai Key Laboratory of Signaling and Diseases Research, School of Life Science and Technology, Tongji University, Shanghai 200092, China; lei.xue@tongji.edu.cn maxianjue@westlake.edu.cn zxpkxy@126.com yangx@queensu.ca.; Zhuhai Interventional Medical Center, Zhuhai Precision Medical Center, Zhuhai People's Hospital, Zhuhai Hospital Affiliated with Jinan University, Zhuhai, Guangdong 51900, China.

Publikováno v: Proceedings of the National Academy of Sciences of the United States of America [Proc Natl Acad Sci U S A] 2020 Dec 01; Vol. 117 (48), pp. 30520-30530. Date of Electronic Publication: 2020 Nov 17.

Identification of Celastrol as a Novel YAP-TEAD Inhibitor for Cancer Therapy by High Throughput Screening with Ultrasensitive YAP/TAZ-TEAD Biosensors.

Autor: Nouri K; Department of Pathology and Molecular Medicine, Queen's University, Kingston, ON K7L 3N6, Canada. kazem.nouri@queensu.ca., Azad T; Department of Pathology and Molecular Medicine, Queen's University, Kingston, ON K7L 3N6, Canada. tahaazad66@gmail.com., Ling M; Department of Pathology and Molecular Medicine, Queen's University, Kingston, ON K7L 3N6, Canada. min.ling@queensu.ca., Janse van Rensburg HJ; Department of Pathology and Molecular Medicine, Queen's University, Kingston, ON K7L 3N6, Canada. 8vrhjj@queensu.ca., Pipchuk A; Department of Pathology and Molecular Medicine, Queen's University, Kingston, ON K7L 3N6, Canada. 15ap63@queensu.ca., Shen H; Department of Cancer Genetics and Genomics, Roswell Park Cancer Institute, Buffalo, NY 14263, USA. He.Shen@RoswellPark.org., Hao Y; Department of Pathology and Molecular Medicine, Queen's University, Kingston, ON K7L 3N6, Canada. yh5@queensu.ca., Zhang J; Department of Cancer Genetics and Genomics, Roswell Park Cancer Institute, Buffalo, NY 14263, USA. jianmin.zhang@roswellpark.org., Yang X; Department of Pathology and Molecular Medicine, Queen's University, Kingston, ON K7L 3N6, Canada. yangx@queensu.ca.

Publikováno v: Cancers [Cancers (Basel)] 2019 Oct 19; Vol. 11 (10). Date of Electronic Publication: 2019 Oct 19.